TB Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing (NAT), Skin Test / Mantoux Test (TST), Blood Test / Serology Test, SMEAR Microscopy, Cultured-Based Tests, Radiography Tests, Others), By End-User (Hospitals and Diagnostic Laboratories, Physician’s Office Laboratories, Reference Laboratories, Academics and Research Facilities) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 04, 2026 | Author: Dhanashri Chandgude | Format:

TB Diagnostics Market Market Size & Growth Analysis

The global TB diagnostics market size was valued at USD 1.48 billion in 2025 and is projected to grow from USD 1.56 billion in 2026 to USD 2.41 billion by 2034, registering a CAGR of 5.56% during the forecast period from 2026 to 2034. North America dominated the tuberculosis diagnostics market with a market share of 36.4% in 2025.

TB diagnostics refers to diagnostic tests and procedures used to detect Mycobacterium tuberculosis, the bacterium responsible for tuberculosis (TB), and identify active or latent infections. These methods include molecular tests, sputum microscopy, culture testing, and immunological assays used to support early diagnosis and treatment decisions.

TB Diagnostics Market Key Takeaways

Global Market Size & Growth

Global Market Size (2025)
USD 1.48 billion
Global Market Size (2026)
USD 1.56 billion
Projected Market Size (2034)
USD 2.41 billion
Market CAGR (2026–2034)
5.56%

Regional Insights

Largest Regional Market (2025)
North America
North America Market Share (2025)
36.4%
Fastest-growing Region
Asia Pacific
Asia Pacific CAGR (2026–2034)
7.12%

Segment Insights

By Test Type
Leading Segment
Nucleic Acid Testing (NAT)
Market Share in 2025 30.6%
By End User
Fastest-growing Segment
Reference Laboratories
CAGR 6.52% (2026–2034)
TB Diagnostics Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

TB Diagnostics Market Market Dynamics

01

Rising Need for Drug-Resistance Testing

The rising prevalence of drug-resistant tuberculosis increases the need for tests that identify resistance to commonly used TB medicines. Accurate resistance detection helps healthcare providers select effective treatment regimens and reduce delays in appropriate care. For example, GeneXpert MTB/RIF testing detects tuberculosis bacteria and identifies resistance to rifampicin, supporting early treatment decisions. This growing clinical requirement increases demand for molecular diagnostic platforms, drug-susceptibility tests, and specialized laboratory supplies.

02

Impact Analysis of Key Drivers in TB Diagnostics Market

Drivers

Market Impact

High Burden of Undiagnosed TB Cases

The large number of people with undiagnosed tuberculosis creates demand for expanded diagnostic coverage and routine testing. National health programmes and healthcare providers require greater testing capacity to identify missed cases, increasing demand for sputum testing, laboratory services, and diagnostic consumables.

Rising Need for Drug-Resistance Testing

The prevalence of multidrug-resistant and rifampicin-resistant TB increases the need for tests that identify resistance to specific medicines. Healthcare providers require drug-susceptibility testing to select effective treatment regimens, supporting demand for molecular and culture-based diagnostic tests.

Increasing TB Screening Among High-Risk Groups

People living with HIV, household contacts of TB patients, and individuals with conditions such as diabetes require targeted screening and diagnostic evaluation. These screening needs expand testing volumes across hospitals, community health centres, and specialized diagnostic laboratories.

Expansion of National TB Elimination Programmes

Government-led TB control initiatives increase the procurement of diagnostic equipment, laboratory supplies, and testing services. Public-sector investment and free diagnostic programmes support wider access to TB testing and create institutional demand for diagnostic products.

Growing Need for Laboratory Testing Capacity

Rising diagnostic workloads increase the need for additional laboratory facilities, testing equipment, trained personnel, and reliable consumable supplies. Investments in laboratory infrastructure strengthen testing capacity and support demand for reagents, culture media, and diagnostic instruments.

TB Diagnostics Market Market Segmental Analysis

By Test Type

Nucleic acid testing (NAT) held the largest market share at 30.6%, supported by its high diagnostic accuracy, rapid detection capabilities, and ability to identify tuberculosis infections through molecular analysis. Growing emphasis on early diagnosis and reliable detection of drug-resistant TB further supports its leading position.

Nucleic acid testing is also projected to register the highest CAGR of 7.48%, driven by increasing adoption of molecular diagnostic technologies, expanding access to rapid testing, and greater demand for timely identification of TB and drug resistance.

TB Diagnostics Market Size By Segments

Request Customizationto receive a tailored report.

By End User

Hospitals and diagnostic laboratories accounted for the largest market share at 52.8%, reflecting their role as primary centers for TB screening, diagnosis, and patient management. Established laboratory infrastructure, high patient volumes, and access to multiple diagnostic methods reinforce this segment's dominance.

Reference laboratories are expected to record the highest CAGR of 6.52%, supported by growing demand for specialized testing, confirmatory diagnosis, and advanced detection of drug-resistant tuberculosis. Their testing expertise and ability to process complex diagnostic samples are further driving growth.

TB Diagnostics Market Share By Segments

Speak to an Analystto discuss market opportunities.

TB Diagnostics Market Market Regional Analysis 

North America TB Diagnostics Market Market

The North America tuberculosis diagnostics market accounted for the largest regional share of 36.4% in 2025.

U.S. TB Diagnostics Market

The U.S. market is expected to benefit from continued investment in early TB detection, as the CDC has established a 2030 target of reducing TB incidence to 1.48 cases per 100,000 people, achieving 95% reporting of positive TB nucleic acid amplification test (NAAT) results within six days and 100% reporting of initial drug-susceptibility results, supporting demand for rapid molecular diagnostics and advanced laboratory testing.

Canada TB Diagnostics Market

Canada’s TB diagnostics market is expected to benefit from its national elimination commitment, as the federal government aims to achieve pre-elimination of TB across Canada by 2035 and eliminate TB among Inuit communities across Inuit Nunangat by 2030, requiring expanded screening, early detection and access to rapid molecular tests, particularly for drug-resistant TB.

North America TB Diagnostics Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific TB Diagnostics Market Market

The Asia Pacific tuberculosis diagnostics market is expected to grow at a CAGR of 7.12% during the forecast period 2026–2034, showcasing the fastest-growing regional market.

Japan TB Diagnostics Market

Japan’s TB diagnostics market is expected to benefit from strengthened screening initiatives, as the Ministry of Health, Labour and Welfare targets reducing the TB incidence rate to 2 cases per 100,000 population by 2035, while its Pre-Entry Tuberculosis Screening programme is being expanded to additional countries in 2026, supporting demand for TB screening and confirmatory diagnostic tests.

China TB Diagnostics Market

China’s National TB Prevention and Control Plan (2024–2030) targets reducing TB incidence to fewer than 43 cases per 100,000 population by 2030, increasing contact screening coverage to at least 90%, the pathogen-confirmation rate to 70%, and drug-resistance testing coverage among bacteriologically positive patients to 95%, supporting demand for molecular diagnostics and drug-susceptibility testing.

India TB Diagnostics Market

India’s TB diagnostics market is expected to benefit from continued expansion of diagnostic infrastructure, as the government has announced plans to add 1,000 AI-enabled handheld chest X-ray devices to its TB screening network, alongside the expansion of molecular testing and early-detection initiatives to strengthen nationwide case identification.

Europe TB Diagnostics Market Market

The Europe tuberculosis diagnostics market accounted for the regional share of 27.6% in 2025.

U.K. TB Diagnostics Market

The U.K. market is expected to benefit from continued investment in TB screening and early detection, as the UK Health Security Agency and NHS England target a 90% reduction in TB incidence by 2035, while the national TB Action Plan promotes wider access to WHO-recommended rapid diagnostic tests as the initial method of TB diagnosis.

Germany TB Diagnostics Market

Germany’s TB diagnostics market could benefit from stronger screening and early-detection initiatives, as the WHO End TB Strategy targets a 90% reduction in TB incidence by 2035 compared with 2015, while the Robert Koch Institute highlights active case finding and contact investigations as key priorities for improving early diagnosis and preventing transmission.

Competitive landscape

The TB diagnostics market is moderately fragmented, with participation from established in-vitro diagnostics companies, molecular diagnostic technology providers, medical device manufacturers, clinical laboratory service providers, and specialized infectious disease diagnostic companies. The leading players in the TB diagnostics market are Thermo Fisher Scientific Inc., Becton Dickinson and Company, F. Hoffmann-La Roche Ltd., Qiagen NV, and Hologic Inc., with these five companies estimated to collectively account for approximately 35–40% of the global market share; this is an indicative estimate, as their exact combined share is not publicly disclosed.

Established players primarily compete on diagnostic accuracy, test sensitivity and specificity, product reliability, regulatory approvals, extensive distribution networks, manufacturing capacity, affordability, and relationships with hospitals, laboratories, and public health organizations. Emerging players generally compete through rapid diagnostic technologies, point-of-care testing solutions, portable diagnostic platforms, cost-effective molecular assays, simplified testing procedures, improved accessibility, and solutions designed for resource-limited healthcare settings.

List of Key and Emerging Players in TB Diagnostics Market

Thermo Fisher Scientific Inc. (U.S.)
Becton, Dickinson and Company (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
QIAGEN N.V. (Netherlands)
Hologic, Inc. (U.S.)
bioMérieux SA (France)
Oxford Immunotec Ltd. (United Kingdom)
Cepheid, Inc. (U.S.)
Akonni Biosystems, Inc. (U.S.)
Par Pharmaceutical, Inc. (U.S.)
Alere Inc. (Abbott) (U.S.)
LIONEX GmbH (Germany)
Creative Diagnostics (U.S.)
Hain Lifescience GmbH (Germany)

Key Industry Developments

May 2026
QIAGEN announced plans to advance its QuantiFERON latent TB testing portfolio with a fully automated Sample-to-Insight workflow and an AI-enabled TB progression risk-stratification tool, supported by a new automation partnership with Inpeco.
March 2026
The World Health Organization issued its first recommendations for near-point-of-care molecular TB tests, tongue-swab specimens, and sputum pooling, expanding the range of diagnostic technologies suitable for decentralized TB detection.
July 2025
The NIIDAN-TB pilot project was launched in Nagpur with AI-assisted mobile TB screening vans and a molecular diagnostic laboratory for drug-resistance testing, expanding advanced tuberculosis detection infrastructure and high-risk population screening.
May 2025
India's TB diagnostics ecosystem continued expanding decentralized molecular testing capacity through portable rapid-testing platforms and broader deployment strategies aimed at moving diagnosis closer to primary and community healthcare settings. The expanding pipeline included biomarker-based point-of-care and near-point-of-care diagnostic products.

Report Scope

Segmentation

By Test Type 7
  • Nucleic Acid Testing (NAT)
  • Skin Test / Mantoux Test (TST)
  • Blood Test / Serology Test
  • SMEAR Microscopy
  • Cultured-Based Tests
  • Radiography Tests
  • Others
By End-User 4
  • Hospitals and Diagnostic Laboratories
  • Physician’s Office Laboratories
  • Reference Laboratories
  • Academics and Research Facilities

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 7
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Thermo Fisher Scientific Inc. (U.S.) · Becton, Dickinson and Company (U.S.) · F. Hoffmann-La Roche Ltd. (Switzerland) · QIAGEN N.V. (Netherlands) · Hologic, Inc. (U.S.)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The tb diagnostics market size is valued at USD 1.56 Billion in 2026 and is projected to reach USD 2.41 Billion by 2034, at a CAGR of 5.56% during the forecast period 2026-2034.
North America dominated the market with a share of 36.4% in 2025.
The leading players in this market are Thermo Fisher Scientific Inc., Becton Dickinson and Company, Hoffmann-La Roche Ltd., Qiagen NV, Hologic Inc..
The tb diagnostics market is projected to grow at a CAGR of 5.56% during the forecast period of 2026 2034.
About the Author
Dhanashri Chandgude
Dhanashri Chandgude
Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now